ResultsHealthcare & Life Sciences
Redcliffe Labs revenue FY24: Rs 348.38 crore, net loss Rs 250 crore
Redcliffe Labs narrows losses in FY24
By Abha Lohia · Editor ·
Redcliffe Labs revenue
Redcliffe Labs reported revenue of Rs 348.38 crore in FY24, with a net loss of Rs 250 crore, as reported by Entrackr on 10 December 2024.
| Revenue (FY24) | Rs 348.38 crore |
|---|---|
| Net loss (FY24) | Rs 250 crore |
Redcliffe Labs: revenue and funding and every story →
Founded 2018
- Redcliffe Labs operates a network of pathology and radiology laboratories across India
- It reported FY24 revenue of Rs 348 crore, up 11%, and cut losses by 28% to Rs 250 crore
- The company spent Rs 1.6 to earn every rupee, with EBITDA margin at -57.55%
What happened
- Redcliffe Labs reported its FY24 financial results.
- Revenue from operations rose 11% to Rs 348.38 crore from Rs 313.86 crore in FY23.
- Total income, including other income, crossed Rs 353 crore.
- Losses narrowed 28% to Rs 250 crore from Rs 345 crore in the previous year.
- Advertising costs fell 45% to Rs 65.38 crore, and material costs dropped 15% to Rs 106.31 crore.
- Laboratory test charges increased 62.2%, and depreciation costs grew three times.
- Total expenses declined 14% to Rs 556.16 crore from Rs 647.30 crore.
- The company spent Rs 1.6 to earn every rupee, with an EBITDA margin of -57.55%.
Why it matters
- The diagnostics category faces growth challenges despite a larger overall market than before 2020.
- Competitors like Tata 1mg reported Rs 1,968 crore revenue in FY24, while Healthians achieved EBITDA profitability on Rs 243 crore revenue.
- Thyrocare posted a 20% revenue jump to Rs 177.4 crore in Q2 FY25 with a profit of Rs 26.4 crore.
- Redcliffe Labs recently secured $42 million in Series C funding and acquired Celara Diagnostics for about $7 million.
The business
- Redcliffe Labs operates a network of self-owned certified labs and collection centres for pathology and radiology testing.
- It offers health checkup packages, smart reports with colour-coded insights, expert consultation, AI assistance, and diet plans.
- Services include home sample collection, temperature-controlled sample transfer, and MD pathologist-verified reports.
- The company has a she-centric diagnostic platform called Femcliffe Health Packages.
- It also offers GeneCliffe tests for DNA, chromosome, and protein insights, and HealthEx curated by genetic experts.
- The website claims 1 crore+ lives touched, 80+ self-owned certified labs, 2,000+ collection centres, and 1,500+ trained phlebotomists.
The founders
Who put in money
- Leapfrog Investments existing
In numbers
Rs 348.38 croreRevenue from operations · FY24
Rs 313.86 croreRevenue from operations · FY23
Rs 353 croreTotal income · FY24
Rs 250 croreLosses · FY24
Rs 345 croreLosses · FY23
Rs 65.38 croreAdvertising costs · FY24
Rs 106.31 croreMaterial costs · FY24
Rs 556.16 croreTotal expenses · FY24
Rs 647.30 croreTotal expenses · FY23
-544.68%ROCE · FY24
-57.55%EBITDA margin · FY24
Rs 15.87 croreCash and bank balances · FY24
Rs 89.64 croreCurrent assets · FY24
Rs 341.02 croreDiagnostic services revenue · FY24
Rs 2.16 croreSale of products · FY24
Rs 5.20 croreOther operating income · FY24
$113 millionTotal funding to date
$42 millionSeries C funding
Earlier rounds
- Series C · $42 million
Up against
PharmEasy-owned ThyrocareHealthiansTata 1mg
Words to know
- EBITDA margin
- Earnings before interest, taxes, depreciation, and amortisation as a percentage of revenue; a measure of operating profitability.
- ROCE
- Return on capital employed; a ratio that shows how efficiently a company uses its capital to generate profits.
- Diagnostic services
- Medical tests and procedures used to identify a disease or condition, such as blood tests and imaging.
The numbers around it
Redcliffe Labs has 4 funding rounds in StopDown's archive, $115 Mn raised in all.
| When | Round | Amount | Led by |
|---|---|---|---|
| 17 September 2024 | Series C | $42M | IFU (Denmark's Investment Fund for Developing Countries) |
| 13 August 2023 | growth | $80 million | |
| 29 September 2022 | Series B | $100-125 million | |
| 6 May 2022 | Series B | $61M | LeapFrog Investments |
Terms in this story
- EBITDA: EBITDA is earnings before interest, tax, depreciation and amortisation, a measure of operating profit before financing and accounting charges. It is not the same as net profit. In Indian startup results, check whether EBITDA includes ESOP costs, since adjusted versions often leave them out.
- Financial year: An Indian financial year runs from 1 April to 31 March, and it is named after the year it ends. FY26 means April 2025 to March 2026. Startup results for a year arrive months after it closes, so a November 2026 story may still be about FY25.
- Profitability: Profitable can mean five different things in a startup headline: profit after tax, positive EBITDA, positive adjusted EBITDA, positive cash flow or profit on each order. Only the first is a profit in the full accounting sense. Always check which one a story means.
Read next
FundingRedcliffe Lifetech raises $61 million Series BRedcliffe Lifetech is an omnichannel diagnostics platform offering 3,500+ pathology and genetic testsFundingAugust AI raises $12M for US expansionAugust AI offers an AI health assistant that answers medical questions through WhatsApp and a mobile appFundingVitusCare raises $3 million Series BVitusCare runs dialysis units inside partner hospitals, which keeps costs low, and has grown from 22 to over 60 centres
Everything on Redcliffe Labs → · All startup news on 10 December 2024 →
Is this Redcliffe Labs? Get your “Featured on StopDown” badge →